Catalyst
Slingshot members are tracking this event:
Topline Results for Ritter's (RTTR) Phase 2b/3 Trial of RP-G28 in Lactose Intolerance Expected in Q1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RTTR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 28, 2017
Occurred Source:
http://www.ritterpharmaceuticals.com/ritter-pharmaceuticals-announces-lactose-intolerance-treatment-rp-g28-demonstrated-efficacy-and-clinically-meaningful-benefit-in-phase-2b3-clinical-trial-data-supports-further-clinical-development
Related Projects
- Discussing RP-G28 for Lactose Intolerance with the author of the Manuscript detailing the clinical results, published in Nutrition Journal. RTTR Executed On: Sep 22, 2016 at 10:30 AM EDT
Related Keywords
Rp-g28, Lactose Intolerance, Phase 2b/3, Top-line Results
